Main Article Content
Introduction: Early onset breast cancer (occuring under age 40) tend to exhibit a different, aggressive phenotype, and are usually associated with hereditary BRCA1 or BRCA2 mutations. We investigated the levels of Hsp27 and HER2/Neu, as well as ER positivity, in early onset breast cancer patients.
Materials and methods: Eighteen paraffin blocks of tissues from patients diagnosed with invasive ductal carcinoma of no specific type (IDC-NST) regardless of grade or stage, age below 39 years (mean 34 years) who underwent surgery or surgical biopsy in Dr. Soetomo General Hospital, Surabaya, within the period of January 2014 - December 2014, were examined for Hsp27 expression, estrogen receptor status, and HER2/Neu amplification. The control group consisted of blocks from 112 patients diagnosed with IDC-NST aged older than 40 who underwent resection within the same period; all specimen in the control group is also stained for Hsp27 and tested for ER and HER2/Neu status.
Results: Examined blocks gained from the younger patient pool typically has higher grade, were negative for estrogen receptor status and show less Hsp27 expression. Sixteen (88.9%) of early-onset patients has grade II or III cancer, with 55.55% presenting with grade III cancer. Meanwhile, 79 (70.53%) of late onset patient has grade II or III cancer, with 26.78% presenting with grade III cancer. Seventy-seven out of 112 (68.75%) patients aged 50 or older has positive ER status, while only 8 out of 18 (45.45%) of early-onset patients have positive ER status. All patients aged 50 years and below show Hsp27 score that is less than the median score, while from all patients aged 50 or above, 64 out of 96 (66.66%) samples exceed the median score. Meanwhile, HER2/Neu scoring distribution seem to be similar across age groups.
Conclusion: Difference in estrogen receptor expression and Hsp27 levels show a significant difference between early-onset and late-onset breast cancer patients. Meanwhile, HER2/Neu amplicafication shows similarities between early-onset and late-onset patients.
© Journal of Asian Medical Students’ Association (JAMSA). Released under a Creative Commons license.
2. Sinn H. P & Kreipe H. A brief overview of the WHO classification of breast tumours, 4th edition. Breast Care (Basel), 8(2), 149-154. DOI: 10.1159/000350774
3. Dumitrescu R. G & Cotarla I. Understanding breast cancer risk: where do we stand in 2005? Journal of Cell Molecular Medicine, 2005, 9 (1): 208-221.
4. Pointon K. S. & Cunningham D. A. Ultrasound findings in pure invasive lobular carcinoma of the breast: comparison with matched cases of invasive ductal carcinoma of the breast. Breast, 1998, 8: 188-90
5. Putti T. C. et al. Estrogen-receptor negative breast carcinomas: a review of morphology and immunophenotypical analysis. Modifications in Pathology, 2005, 18: 26-35.
6. Maynard P. V. et al. Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Research, 1978, 38: 4292-5
7. Slamon D. J. et al. Use of chemotherapy plus monoclonal
antibody against HER2 for metastatic breast cancer that overexpress HER2. New England J of Medicine, 2001, 344: 783-92. DOI: 10.1056/NEJM200103153441101
8. Cheang M. C. et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinical Cancer Research, 2008, 14: 1368-76.
9. Tischkowitz M. et al. Use of immunohistochemical markers can refine prognosis in triple-negative breast cancer. BMC Cancers, 2007, 7: 134-9.
10. Oesterreich S. et al. Basal regulatory promoter elements of the hsp27 gene in human breast cancer cells. Biochemical and Biophysical Research Communications, 1996, 222 (1): 155-63
11. Porter W. et al. Role of estrogen receptor/Sp1 complexes in oestrogen-induced heat shock protein 27 gene expression. Molecular Endocrinology, 1996, 10 (11)
12. Nakashima R. et al. Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. Nature, 2011, 480 (7378): 565-569
13. Blackburn R. V. et al. Comparison of tumor growth between hsp-27 transfected murine L292 cells in nude mice. International Journal of Cancer, 1997, 72: 871-7
14. Shin K. D. et al. Blocking tumor cell migration and invasion with bipheny isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. Journal of Biological Chemistry, 2005, 280: 41439-48
15. Calderwood S. K. et al. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends in Biochemical Science, 2006, 31 (3): 164-172
16. Sundquist M. et al. Incidence and prognosis in early onset breast cancer. The Breast, 2002, 11: 30-5
17. Marcus J N et al. Hereditary breast cancer: pathobiology, prognosis, and BRCAl and BRCA2 gene linkage. Cancer 1996; 77: 697–709
18. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997; 349: 1505–1510.
19. Wang L & Di LJ. BRCA1 and estrogen receptor in breast cancer: where they interact? International J of Biol Sci 2014; 10(5): 566-75